Diabetic Retinopathy Market Report 2026

Diabetic Retinopathy Market Overview

• Diabetic Retinopathy market size has reached to $9.26 billion in 2025 • Expected to grow to $13.54 billion in 2030 at a compound annual growth rate (CAGR) of 8% • Growth Driver: Exploring The Diabetic Retinopathy Market In A Diabetic-Prevalent World • Market Trend: AI Partnerships Transforming Diabetic Retinopathy Screening • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Diabetic Retinopathy Market?

Diabetic retinopathy is a complication of diabetes that affects the retina, the light-sensitive tissue at the back of the eye, resulting from damage to blood vessels caused by prolonged high blood sugar levels; this condition can lead to vision loss and even blindness if not properly managed, making regular eye examinations essential for early detection and treatment. The main diabetic retinopathy types are proliferative diabetic retinopathy, and non-proliferative diabetic retinopathy. Proliferative diabetic retinopathy refers to the advanced stage in which aberrant new blood vessels develop on the retina's surface. The various treatment methods are anti-vegf drugs, intraocular steroid injection, laser photocoagulation, and vitreoretinal surgery used in hospitals, ambulatory surgical centers, and others.

What Is The Diabetic Retinopathy Market Growth Forecast?

The diabetic retinopathy market size is expected to see strong growth in the next few years. It will grow to $13.54 billion in 2030 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to growth of ai-assisted screening tools, expansion of ophthalmology clinics, increasing anti-vegf therapy adoption, focus on preventive eye care, rising aging diabetic population. Major trends in the forecast period include rising adoption of retinal screening programs, increased use of anti-vegf therapies, expansion of early detection and monitoring, growing integration of AI-based retinal imaging, rising focus on vision preservation.

Global Diabetic Retinopathy Market Segmentation

1) By Type: Proliferative Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy 2) By Treatment: Anti-VEGF Drugs, Intraocular Steroid Injection, Laser Photocoagulation, Vitreoretinal Surgery 3) By End-User: Hospitals, Ambulatory Surgical Centers, Other End Users Subsegments: 1) By Proliferative Diabetic Retinopathy (PDR): Neovascularization, Vitreous Hemorrhage, Tractional Retinal Detachment 2) By Non-Proliferative Diabetic Retinopathy (NPDR): Mild NPDR, Moderate NPDR, Severe NPDR

What Is The Driver Of The Diabetic Retinopathy Market?

The rising prevalence of diabetes is expected to propel the growth of the diabetic retinopathy market going forward. Diabetes refers to a long-term metabolic disease that causes high blood glucose levels. The rise in the prevalence of diabetes is mainly driven by overweight, obesity, genetics, and physical inactivity, whereas patients with diabetes have too much sugar in their blood, which can damage the retina, which is part of the eye that detects light and sends signals to your brain through a nerve in the back of eye. For instance, in March 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while for type 2 diabetes, it rose by 21%. The proportion of people meeting target HbA1c levels also reached 37.9%, the highest ever recorded by the National Diabetes Audit. Therefore, the rising prevalence of diabetes is driving the growth of the diabetic retinopathy industry.

Key Players In The Global Diabetic Retinopathy Market

Major companies operating in the diabetic retinopathy market are Pfizer Inc., F‑Hoffmann‑La Roche Ltd., Bayer AG, Novartis AG, Regeneron Pharmaceuticals Inc., Allergan plc., Genentech Inc., Santen Pharmaceutical Co Ltd., Carl Zeiss Meditec AG, Lumenis Ltd., Optos Plc., Quantel Medical SAS, NIDEK Co Ltd., IRIDEX Corporation, Alimera Science Inc., Oxurion NV, EyePoint Pharmaceuticals, Opthea Limited, KalVista Pharmaceuticals Inc., Regenxbio Inc., Kodiak Sciences Inc., Oculis, Verseon International Corporation, Clearside Biomedical Inc.

Global Diabetic Retinopathy Market Trends and Insights

Major companies operating in the diabetic retinopathy market are focused on partnerships to increase their profitability in the market. Partnerships in diabetic retinopathy refer to collaborative efforts between various stakeholders, such as healthcare providers, researchers, pharmaceutical companies, and advocacy groups, to address the challenges associated with diabetic retinopathy. For instance, in October 2023, AEYE Health, a US-based provider of AI-based diagnostics for retinal imaging collaborated with Topcon Screen, a Japan-based diabetic screening platform. The goal of their collaboration is to provide point-of-care screening for diabetic retinopathy using artificial intelligence, ensuring swift and precise results, so that primary care clinicians can directly conduct diabetic retinopathy screenings in their clinics. This approach aims to reduce the chances of non-compliance and address care gaps associated with diabetic retinopathy screening by offering immediate, accurate assessments at the point of care.

What Are Latest Mergers And Acquisitions In The Diabetic Retinopathy Market?

In January 2025, Regeneron Pharmaceuticals Inc, a US–based biotechnology company, acquired Oxular Limited for an undisclosed amount. With this acquisition, Regeneron gains access to Oxular’s proprietary sustained-release Oxuspheres technology and its Oxulumis suprachoroidal microcatheter delivery system, thereby enhancing its retinal drug-delivery capabilities while improving its operational scale and therapeutic reach in ophthalmic care. Oxular Limited is a UK–based biotechnology company focused on developing long-acting drug formulations and targeted delivery solutions for retinal diseases, known for its lead candidate OXU-001 and its integrated drug-device platform for posterior-segment disorders.

Regional Outlook

North America was the largest region in the diabetic retinopathy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Diabetic Retinopathy Market?

The diabetic retinopathy market includes revenues earned by entities by providing ophthalmologic examination, eye management and retinal imaging and monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Diabetic Retinopathy Market Report 2026?

The diabetic retinopathy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic retinopathy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.